These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27107723)

  • 1. Lipophilic nalmefene prodrugs to achieve a one-month sustained release.
    Gaekens T; Guillaume M; Borghys H; De Zwart LL; de Vries R; Embrechts RC; Vermeulen A; Megens AA; Leysen JE; Herdewijn P; Annaert PP; Atack JR
    J Control Release; 2016 Jun; 232():196-202. PubMed ID: 27107723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
    Costantini LC; Kleppner SR; McDonough J; Azar MR; Patel R
    Int J Pharm; 2004 Sep; 283(1-2):35-44. PubMed ID: 15363499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection.
    Papich MG; Narayan RJ
    Drug Deliv Transl Res; 2022 Feb; 12(2):376-383. PubMed ID: 34817831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
    Kyhl LE; Li S; Faerch KU; Soegaard B; Larsen F; Areberg J
    Br J Clin Pharmacol; 2016 Feb; 81(2):290-300. PubMed ID: 26483076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of the opioid antagonist, nalmefene, in rat and dog.
    Murthy SS; Mathur C; Kvalo LT; Lessor RA; Wilhelm JA
    Xenobiotica; 1996 Jul; 26(7):779-92. PubMed ID: 8819305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
    Krieter P; Gyaw S; Crystal R; Skolnick P
    J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
    Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
    Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.
    Matzke GR; Frye RF; Alexander AC; Reynolds R; Dixon R; Johnston J; Rault RM
    J Clin Pharmacol; 1996 Feb; 36(2):144-51. PubMed ID: 8852390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nalmefene: radioimmunoassay for a new opioid antagonist.
    Dixon R; Hsiao J; Taaffe W; Hahn E; Tuttle R
    J Pharm Sci; 1984 Nov; 73(11):1645-6. PubMed ID: 6520774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
    Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H
    Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo release of dinalbuphine sebacate extended release formulation: Effect of the oil ratio on drug release.
    Li CJ; Ku MY; Lu CY; Tien YE; Chern WH; Huang JD
    Int J Pharm; 2017 Oct; 531(1):306-312. PubMed ID: 28847670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies.
    Chou JZ; Albeck H; Kreek MJ
    J Chromatogr; 1993 Apr; 613(2):359-64. PubMed ID: 8491826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Jallad NS; Wilhelm JA; Bikhazi GB
    Br J Clin Pharmacol; 1996 Sep; 42(3):301-6. PubMed ID: 8877019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers].
    Liao RF; Zeng ZP; Wen YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1816-9. PubMed ID: 18971181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose.
    Crystal R; Ellison M; Purdon C; Skolnick P
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):58-69. PubMed ID: 37496452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin.
    Stinchcomb AL; Swaan PW; Ekabo O; Harris KK; Browe J; Hammell DC; Cooperman TA; Pearsall M
    J Pharm Sci; 2002 Dec; 91(12):2571-8. PubMed ID: 12434400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
    Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
    J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.